Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock Has Average Price Target of $100.25

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given a consensus rating of “Moderate Buy” by the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $100.25.

A number of research firms have commented on ESTA. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Canaccord Genuity Group set a $105.00 price objective on shares of Establishment Labs in a research note on Thursday, August 6th. TD Cowen lifted their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a report on Thursday, August 13th. Finally, BTIG Research reiterated a “buy” rating and issued a $103.00 price target on shares of Establishment Labs in a research note on Tuesday, September 1st.

Establishment Labs Price Performance

NASDAQ ESTA opened at $65.97 on Monday. The business’s fifty day moving average is $77.83 and its 200 day moving average is $74.45. Establishment Labs has a fifty-two week low of $37.37 and a fifty-two week high of $97.59. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The company has a market capitalization of $1.97 billion, a PE ratio of -50.36 and a beta of 1.05.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter in the previous year, the company earned ($0.57) EPS. The business’s quarterly revenue was up 31.7% compared to the same quarter last year. Sell-side analysts predict that Establishment Labs will post -1.15 earnings per share for the current year.

Institutional Trading of Establishment Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in ESTA. Engineers Gate Manager LP lifted its holdings in Establishment Labs by 7.5% in the 2nd quarter. Engineers Gate Manager LP now owns 31,458 shares of the company’s stock worth $2,699,000 after purchasing an additional 2,191 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Establishment Labs during the second quarter valued at approximately $32,000. NewEdge Advisors LLC lifted its holdings in shares of Establishment Labs by 34.9% in the second quarter. NewEdge Advisors LLC now owns 13,871 shares of the company’s stock worth $1,190,000 after buying an additional 3,587 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Establishment Labs by 5.6% in the second quarter. Arizona State Retirement System now owns 5,057 shares of the company’s stock worth $434,000 after buying an additional 268 shares in the last quarter. Finally, Amundi bought a new position in shares of Establishment Labs during the second quarter worth $291,000. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a medical technology company focused on developing, manufacturing and commercializing products for breast aesthetics and reconstruction. Founded in 2004 and headquartered in Alajuela, Costa Rica, the company serves plastic surgeons, healthcare providers and patients in markets around the world.

Its portfolio is centered on the Motiva line of breast implants, including implants designed for cosmetic augmentation and reconstructive procedures. Establishment Labs also develops related technologies and products, including tissue expanders and surgical systems, as well as Mia Femtech, a minimally invasive breast-enhancement procedure and platform.

The company operates internationally through direct sales and distribution partnerships.